机械设备行业 标配 （维持） 7 月挖机内外销同比双增，重大工程有效拉动需求 工程机械行业跟踪点评 2025 年 8 月 21 日 分析师：谢少威（SAC 执业证书编号：S0340523010003） 电话：0769-23320059 邮箱：xieshaowei@dgzq.com.cn 事件： 中国工程机械工业协会公布 2025 年 7 月挖掘机、装载机销量数据。 点评： 挖掘机销量数据：2025年7月，挖掘机销量为17138台，同比增长25.19%，环比下降8.86%。其中，国 内销量为7306台，同比增长17.20%，环比下降10.20%；出口销量为9832台，同比增长31.87%，环比下 降7.84%，占总销量的57.37%，创近两年新高。2025年1-7月，挖掘机累计销量为137658台，同比增长 17.75%。其中，国内累计销量为72943台，同比增长22.67%；出口累计销量为64715台，同比增长13.02%。 2025年7月电动挖掘机销量9台，（6吨以下2台，6至10吨级1台，18.5至28.5吨级4台，28.5至40吨级2 台）。 装载机销量数据：2025年7月，装载机销量为9000台，同比 ...

Core Insights - BYD has surpassed Tesla in sales in key European markets such as the UK and Germany, marking a significant shift in the European automotive landscape [1][2] - The overall export of Chinese automobiles, particularly electric vehicles (EVs), has seen substantial growth, with a notable increase in the export of new energy vehicles [3][4] - The strategy of Chinese automotive companies is evolving from merely exporting vehicles to establishing localized production and supply chains in foreign markets [4][5] Summary by Category Sales Performance - In April, BYD's electric vehicle sales in Europe reached 7,231 units, a 169% year-on-year increase, while Tesla's sales fell by 49% to 7,165 units [2] - In July, BYD's sales in the UK and Germany were 3,184 and 1,566 units respectively, with Germany experiencing a nearly 390% year-on-year growth [2] Export Growth - In the first half of the year, China exported 3.083 million vehicles, a 10.4% increase year-on-year, with 1.06 million of those being new energy vehicles, reflecting a 75.2% increase [1][3] - The export of new energy passenger vehicles reached 1.011 million units, up 71.3% year-on-year, with plug-in hybrids and hybrids becoming new growth points [3] Strategic Shift - Chinese automotive companies are transitioning from "going out" to "going in," focusing on local production and establishing a presence in foreign markets [4] - BYD's new factory in Brazil, with a planned capacity of 150,000 vehicles, aims to create 20,000 local jobs and foster local supply chain partnerships [4] - New entrants like XPeng and Leap Motor are also exploring localized production, with XPeng launching its first overseas production project in Indonesia [5]

Core Viewpoint - The company reported strong financial performance in the first half of 2025, with significant growth in net profit and a stable revenue increase, indicating robust operational capabilities and market position [2][3]. Financial Performance - In H1 2025, the company achieved revenue of 579 million yuan, a year-on-year increase of 6.69% [2]. - The net profit attributable to shareholders reached 189 million yuan, reflecting a substantial growth of 31.41% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 185 million yuan, up 39.97% year-on-year [2]. Product Performance - The core business of diagnostic reagents generated revenue of 483 million yuan, a year-on-year increase of 7.93%, accounting for 83.4% of total revenue with a gross margin of 90.72% [3]. - Revenue from testing services was 32.5 million yuan, a slight increase of 0.92%, with a gross margin of 48.66% [3]. - Revenue from drug clinical research services was 56.99 million yuan, down 5.00% year-on-year, with a gross margin of 53.14% [3]. Regional Sales - Domestic sales amounted to 442 million yuan, growing by 7.11% year-on-year [3]. - International sales and pharmaceutical business revenue reached 137 million yuan, an increase of 5.36% year-on-year [3]. R&D and Product Pipeline - The company invested 90.53 million yuan in R&D, representing 15.63% of total revenue, ensuring technological leadership [4]. - The company obtained 2 new Class III medical device registration certificates, bringing the total to 32, indicating a comprehensive and industry-leading product range [4]. - Five products, including human homologous recombinant repair defect detection kits, are in the review stage, with three included in innovation or priority approval processes [4]. International Expansion - The company has established partnerships with major pharmaceutical companies like AstraZeneca, Eli Lilly, Johnson & Johnson, and Pfizer for companion diagnostics [5]. - An international business team covering over 60 countries and regions has been established, indicating ongoing efforts in overseas expansion [5].

Core Viewpoint - The company aims to enhance its operational quality and profitability through the "Quality Improvement and Efficiency Enhancement Return Action Plan" for 2025, building on the success of the 2024 plan, which resulted in significant revenue and profit growth [1][2]. Group 1: Business Performance - In 2024, the company's revenue reached 15.839 billion yuan, a year-on-year increase of 40.63%, while net profit attributable to shareholders also saw substantial growth [1]. - The company is focusing on its core business, leveraging the recovery in consumer demand and health trends to drive innovation and expand into new product categories such as electrolyte drinks and sugar-free tea [1][2]. Group 2: Strategic Goals - The company has set a target for 2025 to achieve at least 20% growth in both revenue and net profit [2]. - The strategy includes fostering a diversified product matrix, enhancing brand building, and advancing digital transformation to improve operational efficiency [2]. Group 3: Governance and Compliance - The company is committed to strict compliance with relevant laws and regulations, continuously improving its internal governance structure to protect the rights of investors, especially minority shareholders [3][4]. - The internal control system focuses on compliance and risk management, ensuring transparency and accountability in decision-making processes [3][4]. Group 4: Investor Relations and Communication - The company emphasizes stable dividends to enhance investor confidence, having distributed a total of 5.3 billion yuan in cash dividends since its listing, maintaining a cash dividend ratio of around 50% [4][5]. - Efforts are being made to improve the quality of information disclosure, ensuring that investors receive timely and accurate updates on the company's performance and strategic direction [5][6][7].

Core Viewpoint - The frozen food industry is facing significant challenges in 2024, with Sanquan Foods experiencing a decline in both revenue and net profit for the second consecutive year, marking a notable downturn since its IPO in 2008 [1] Group 1: Financial Performance - In 2024, Sanquan Foods' revenue decreased by 6% to 6.632 billion yuan, while net profit fell by 27.64% to 542 million yuan [1] - The company reported its worst first-quarter performance since 2021, continuing the trend of declining earnings [1] - The revenue from frozen staple foods, which has historically contributed over 80% to the company's income, has shown significant volatility from 2020 to 2024 [2][4] Group 2: Market Dynamics - The decline in revenue for frozen staple foods is attributed to weak consumer demand, a decline in supermarket channels, and intensified industry competition [1] - The sales volume of frozen staple foods saw a slight increase, but revenue fell nearly 4% year-on-year, indicating a strategy of price reduction to maintain market share [1] - The core products "tangyuan, dumplings, and zongzi" experienced revenue fluctuations, with declines of -8.07%, 3.92%, -15.74%, and -5.84% from 2021 to 2024 [4] Group 3: Product and Channel Strategy - Despite a 2.04% increase in sales volume for frozen staple foods, revenue decreased by 3.95%, highlighting a "volume increase but weak profit" scenario [5] - The company is attempting to diversify its product offerings and has launched new series of dumplings and tangyuan in 2024 [9] - Sanquan Foods is also focusing on e-commerce, which saw a revenue increase of 58.5% in 2024, although it still represents less than 6% of total revenue [5][9] Group 4: International Expansion - In response to domestic market pressures, Sanquan Foods plans to invest in a production base in Australia and expand into markets in Australia, New Zealand, and Southeast Asia [11] - The planned investment for the overseas production base is approximately 2.8 billion Australian dollars (about 1.32 billion yuan), which poses challenges related to consumer preferences, supply chain integration, and regulatory compliance [11]

Investment Rating - The industry investment rating is maintained at "Market Weight" [36] Core Viewpoints - In June 2025, excavator sales reached 18,804 units, a year-on-year increase of 13.26% and a month-on-month increase of 3.31%. Domestic sales were 8,136 units, up 6.20% year-on-year but down 3.05% month-on-month. Export sales were 10,668 units, up 19.30% year-on-year and 8.75% month-on-month, accounting for 56.73% of total sales [2] - Loader sales in June 2025 totaled 12,014 units, reflecting a year-on-year increase of 11.30% and a month-on-month increase of 14.04%. Domestic sales were 6,015 units, up 13.58% year-on-year but down 0.36% month-on-month. Export sales were 5,999 units, up 9.11% year-on-year and 33.37% month-on-month [3] - The average working hours and operating rates of major construction machinery products decreased by 8.56% and 2.65 percentage points respectively, indicating weak terminal demand. However, the report suggests that sufficient project reserves in domestic downstream sectors could enhance operating rates if funding is timely [4] Summary by Sections Excavator Sales - June 2025 excavator sales: 18,804 units, +13.26% YoY, +3.31% MoM - Domestic sales: 8,136 units, +6.20% YoY, -3.05% MoM - Export sales: 10,668 units, +19.30% YoY, +8.75% MoM, 56.73% of total sales - H1 2025 cumulative sales: 120,520 units, +16.77% YoY [2] Loader Sales - June 2025 loader sales: 12,014 units, +11.30% YoY, +14.04% MoM - Domestic sales: 6,015 units, +13.58% YoY, -0.36% MoM - Export sales: 5,999 units, +9.11% YoY, +33.37% MoM - H1 2025 cumulative sales: 64,769 units, +13.59% YoY [3] Market Outlook - The report highlights a positive outlook for overseas expansion of domestic manufacturers, which is expected to enhance global penetration of domestic equipment. The export trade value of construction machinery in May 2025 was $5.024 billion, up 8.64% YoY, while the cumulative export value from January to May was $23.097 billion, up 9.00% YoY [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 91.84 CNY [1][4]. Core Viewpoints - The company is transitioning from "product export" to "supply chain + brand export," with a significant investment of 220 million CNY in establishing its first overseas factory in Thailand, focusing on konjac and potato chip categories [3]. - The company aims to achieve a 10%-20% share of overseas business within 3-5 years, indicating a strategic shift towards globalization [3]. - The financial performance remains robust, with projected net profits for 2025-2027 at 783 million CNY, 999 million CNY, and 1.215 billion CNY respectively, despite adjustments due to raw material and labor cost fluctuations [4][8]. Financial Summary - The company’s revenue is expected to grow from 4.115 billion CNY in 2023 to 9.190 billion CNY by 2027, reflecting a compound annual growth rate (CAGR) of 17.1% [6]. - The net profit margin is projected to stabilize around 12% over the forecast period, with net profit growth rates of 67.8%, 26.5%, and 22.3% for the years 2023, 2024, and 2025 respectively [6][10]. - The company’s earnings per share (EPS) are forecasted to increase from 1.85 CNY in 2023 to 4.45 CNY in 2027 [6][10].

Core Viewpoint - Company is transitioning from "product export" to "supply chain + brand export," aiming to establish a global growth trajectory through local manufacturing and branding strategies [1][2] Group 1: Overseas Expansion Strategy - Company announced an investment of 220 million yuan to establish its first overseas factory in Thailand, focusing on konjac and potato chip products, leveraging local low-cost raw materials and labor advantages [1] - The chairman set a target for overseas business to account for 10%-20% of total revenue within 3-5 years, indicating a significant strategic shift towards international markets [1] Group 2: Market Potential and Product Performance - The konjac market is experiencing rapid growth, with the "Big Devil" konjac product projected to achieve a 76% year-on-year revenue increase in 2024, highlighting its status as a phenomenon in the industry [1] - The Chinese konjac snack market has surpassed 30 billion yuan, with an expected five-year CAGR of 28%, indicating strong growth potential [1] Group 3: Channel and Organizational Evolution - The company is undergoing a channel transformation, with the share of supermarkets decreasing from 54% in 2017 to 3.6% in 2024, while e-commerce and new retail channels now account for over 96% [1] - The company has established a foundation for "standardized replication" across supply chain, branding, and channels, supporting its ability to replicate success in overseas markets [1] Group 4: Financial Performance and Projections - In Q1 2025, the company reported revenue of 1.537 billion yuan, a 25.7% increase, and a net profit of 178 million yuan, an 11.6% increase, with a net profit margin of 11.5% [2] - The gross profit margin was 28.5%, down 3.6 percentage points year-on-year, primarily due to changes in channel and product category structures [2] - Forecasts for net profit attributable to the parent company for 2025-2027 are 783 million yuan, 999 million yuan, and 1.215 billion yuan, reflecting adjustments due to fluctuations in raw material and labor costs [2]

Group 1: Company Overview and Product Development - The company focuses on innovative drugs primarily in cardiovascular, urology, oncology, and respiratory systems, with 6 innovative drugs in development, including 1 in Phase III, 2 in Phase I, and 3 in preclinical research [2] - The product Aipulete has shown strong market performance, with projected sales of 119 million tablets in 2024, representing a 30.28% increase from the previous year [2] - The company emphasizes innovation-driven development strategies, enhancing R&D platforms, increasing investment in technology innovation, and promoting digital transformation and sustainable development [2] Group 2: Export Strategy and International Development - The company primarily exports raw materials to markets in North America, Eastern Europe, Southeast Asia, South America, and Oceania [3] - The company established Unioncle Pharma LLC in the U.S. in 2023 to facilitate international collaboration and accelerate the internationalization of its R&D products [3] - The company is actively seeking opportunities for its newly developed raw materials through various channels to enhance its global presence [3] Group 3: Strategic Acquisitions - The company acquired Longyi Pharmaceutical to strengthen its market presence in Southwest China, aiming to create a dual-core driving pattern with its headquarters in the Yangtze River Delta [4] - Longyi Pharmaceutical has a dense distribution network and advantages in the outpatient market, which will accelerate the regional penetration of the company's existing products [4] - The company's national sales system will provide Longyi Pharmaceutical with more upstream pharmaceutical cooperation resources, expanding its wholesale categories [4]

1. Reported Industry Investment Rating - No information provided 2. Core View of the Report - The motorcycle industry in China shows steady growth, with intensified domestic competition and continuous growth in foreign exports. The trend of Chinese motorcycles going global is positive, and domestic motorcycle brands have greater structural opportunities in overseas markets than in total volume [24]. - The company aims to achieve revenue of over 19 billion yuan in 2025, and plans to conduct mid - term dividends in 2025 under eligible conditions [27]. - The company will work with its controlling shareholder to optimize supply chain management and enhance supply chain synergy to strengthen market competitiveness [28]. 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - The research object is Loncin General, belonging to the transportation equipment industry. The reception time was May 20, 2025. The listed company's reception staff included the chairman, general manager, independent directors, board secretary, and financial controller [17]. 3.2. Detailed Research Institutions - The reception objects include investors and others [20]. 3.3. Research Institution Proportion - No information provided 3.4. Main Content Data - **Motorcycle Industry Development**: In 2024, China's fuel motorcycle sales reached 16.4562 million units, a year - on - year increase of 12.99%. Domestic sales were 8.9065 million units, a year - on - year decrease of 16.56%, and export sales were 11.0163 million units, a year - on - year increase of 26.72% [24]. - **Popular Products of Wujie**: SR250GT redefined the leisure sports scooter market; CU525 became the king of the same - level cruising motorcycles; DS900X had annual sales of over 10,000 units, accounting for over 95% of the total export volume of motorcycles above 800cc in China. New products such as CU250 and RR660S were also launched [24][25]. - **Reasons for Low Domestic Sales of Wujie 900DS**: The most popular product categories in the domestic market are cruising, sports, and scooter models. The domestic leisure and entertainment motorcycle market is still in the development stage, and the sales volume of large - displacement motorcycles is mainly concentrated in the 400 - 600cc range [26]. - **Business in the US and Risk Resistance**: The company's motorcycle exports are mainly to Europe, South America, and Africa. Exports to the US are mainly general machinery products, accounting for less than 7% of total revenue. The company will expand market share in multiple regions and take measures such as "going global in groups" with the supply chain and optimizing overseas manufacturing plant layouts [26]. - **Future Profit Growth Drivers**: The company will follow the strategic path of "product going global → brand going global → production capacity going global", increase the proportion of self - owned brand revenue, optimize the product sales structure, improve operational efficiency, and strengthen risk management [26]. - **2025 Business Plan**: The company will adhere to the business philosophy of "optimizing the existing and breaking through in the new", with a guiding ideology to promote high - quality and sustainable development, and strive to achieve revenue of over 19 billion yuan [26][27]. - **2025 Mid - term Dividend Consideration**: The company has proposed to the general meeting of shareholders to authorize the board of directors to formulate a mid - term dividend plan for 2025 and plans to conduct mid - term dividends under eligible conditions [27]. - **Competition and Supply Chain Integration**: The new controlling shareholder and actual controller of the company have promised to resolve the issue of competing businesses. The company will optimize supply chain management with the controlling shareholder to enhance supply chain synergy [28].